{"id":"NCT03677401","sponsor":"Vyne Therapeutics Inc.","briefTitle":"Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus in Adults With Prurigo Nodularis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-29","primaryCompletion":"2020-01-09","completion":"2020-02-06","firstPosted":"2018-09-19","resultsPosted":"2020-10-28","lastUpdate":"2021-05-20"},"enrollment":295,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pruritus","Prurigo Nodularis"],"interventions":[{"type":"DRUG","name":"5mg Serlopitant Tablets","otherNames":["VPD-737"]},{"type":"DRUG","name":"Placebo Tablets","otherNames":[]}],"arms":[{"label":"5 mg Serlopitant Tablets","type":"EXPERIMENTAL"},{"label":"Matching Placebo Tablets","type":"PLACEBO_COMPARATOR"}],"summary":"Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis","primaryOutcome":{"measure":"Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10","timeFrame":"At Week 10","effectByArm":[{"arm":"Placebo","deltaMin":18.95,"sd":null},{"arm":"Serlopitant 5 mg","deltaMin":25.9,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.158"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":40,"countries":["Austria","Germany","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":148},"commonTop":["Nasopharyngitis","Headache","Fatigue"]}}